High Through-put Discovery of Malaria Drug Targets

疟疾药物靶点的高通量发现

• 批准号: 6485109
• 负责人: John T. Swindle
• 金额: $ 28.4万
• 依托单位: COMPLEGEN, INC.
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-04-15 至 2003-04-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6485109
• 关键词: Plasmodium falciparum; Toxoplasma gondii; antimalarial agents; biotechnology; biotherapeutic agent; cost effectiveness; drug design /synthesis /production; drug discovery /isolation; drug resistance; fungal genetics; genetic library; genome; high throughput technology; immunologic substance development /preparation; immunopharmacology; parasitic disease chemotherapy; yeasts

DESCRIPTION (Provided by applicant): Emerging and re-emerging infectious diseases are some of the most important contributors to pain, suffering and poverty in the developing world. For parasitic diseases in general, vaccines are nonexistent and none are likely to have a significant impact in the foreseeable future. In the case of malaria, without a vaccine on the horizon and an increasing prevalence of resistance to commonly used therapeutic drugs, the need for additional anti-malarial drug development is obvious. However, several factors, including increased cost of development, have lead to the retreat of most pharmaceutical companies from the development of new anti-malarial therapeutics. The research and development described in this proposal utilizes a new cost effective approach to anti-malarial drug target discovery. We will use a comparative approach to identify potential therapeutic targets common to Plasmodium falciparum, Toxoplasma gondii and Eimeria tenella. This work will form the basis for a future phase II application, which will use the reagents developed here to identify broad spectrum apicomplexan specific inhibitor compounds.

描述（由申请人提供）：新兴和重新出现感染力 疾病是痛苦，痛苦和 发展中国家的贫困。对于寄生疾病，疫苗 不存在，没有一个可能对 可预见的未来。在疟疾的情况下，没有疫苗 以及对常用治疗药物的抗药性的越来越多的患病率 显而易见的是，需要进行额外的抗疟疾药物开发。然而， 包括增长成本在内的几个因素已导致 大多数制药公司的撤退 抗菌治疗学。其中描述的研究与发展 提案利用一种新的具有成本效益的方法来抗菌药物目标 发现。我们将使用一种比较方法来识别潜在的治疗 恶性疟原虫，弓形虫gondii和Eimeria tenella共有的靶标。 这项工作将构成未来II期应用程序的基础，该应用将使用 这里开发的试剂旨在鉴定广泛的apicomplexan特异性 抑制剂化合物。